Skip to content
Company Analysis

Johnson & Johnson JNJ

A comprehensive view of key metrics, scores, and financial health for Johnson & Johnson

Overview of Johnson & Johnson

JNJ NYQ
Healthcare Drug Manufacturers - General Mega Cap
Johnson & Johnson (JNJ), is a Mega Cap company, in the Drug Manufacturers - General industry, last closed at $241.52, about 60.4% overvalued vs fair value, +48.3% 1Y return, placing in the top 10% of its sector.
$241.52
-0.21%
As of March 13, 2026
Previous close • Vol 90d: 16.4%
52-Week Range
Market Cap
$587.32B
Enterprise Value
$615.54B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Johnson & Johnson.

Top Beats
No strong beats yet

Quick Facts

Website https://www.jnj.com
HQ New Brunswick, NJ
Employees 138,200
Fiscal year Dec 31

Next Events

Earnings Apr 14 Call: Apr 14

Fair Value Snapshot

Bear Base Bull
$88
$96
$104
Current: $241.52 -60% vs base

Engine Room Money Flow™

Mega Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$94.2B
6%%
Gross Profit
$68.6B
11.7%%
R&D Expense
$14.7B
-14.9%%
Operating Income (EBIT)
$32.6B
86.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
75.3%
Fair

Moderate cash conversion - some working capital drag

Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$18.3B

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
Analysis based on partial data. Some metrics unavailable for complete assessment.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Johnson & Johnson's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
73
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
83
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 77% Coverage
Trade-Off Triangle Visualization A ternary plot showing JNJ's balance between Growth (29.0%), Profitability (38.6%), and Safety (32.4%). Growth 29% Safety 32% Profitability 39%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

52th percentile vs peers
52
Key Signals
Rev Growth YoY 6.0% 57p Revenue CAGR 3Y 5.6% 63p TSR 46.7% 86p EPS CAGR 3Y -9.5% 50p EPS Growth YoY -57.8% 15p
Strengths
  • Interest Coverage Ratio in top 20% of peers (33.55, 95th percentile)
  • Tsr in top 20% of peers (46.7%, 86th percentile)
  • Ebit Margin in top 20% of peers (34.6%, 89th percentile)
  • Net Profit Margin in top 20% of peers (28.5%, 84th percentile)
Risks
  • Eps Growth Yoy in bottom 20% of peers (-57.8%)

Profitability

69th percentile vs peers
70
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

58th percentile vs peers
59
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Johnson & Johnson.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$95.69
- - -
-60.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info